Botulinum toxin is the etiologic agent responsible for the disease botulism. This toxin, which is generally regarded as the most poisonous of all poisons, is known to exist in seven serotypes designated A, B, C, D, E, F and G. Of these seven serotypes, three (A, B and E) account for virtually all cases of human botulism. For botulinum toxin to produce clinical poisoning, it must ordinarily cross at least two membrane barriers. Initially, the toxin binds and undergoes transcytosis across gut or airway epithelial cells. This is the mechanism by which the toxin escapes the lumen of the gut or airway to reach the general circulation. Subsequently, the toxin binds to peripheral cholinergic nerve cells, undergoes receptor-mediated endocytosis and pH-induced translocation, then acts in the cytosol as a zinc-dependent endoprotease to cleave polypeptides that are essential for exocytosis. This is the mechanism by which the toxin produces muscle weakness or flaccid paralysis, which is the characteristic outcome in botulinum toxin poisoning. The goal of the proposed work will be to select botulinum toxin type A as a prototype, to select a human gut epithelial cell line (T-84) as a prototype, and then use these two as models to gain insight into the subcellular and molecular events that account for the ability of the toxin to penetrate membrane barriers. More precisely, two approaches will be used to help elucidate the structural features of the toxin that mediate binding and transcytosis: 1.) a series of truncation mutants will be generated in an attempt to identify the minimal domain that retains the ability to cross gut epithelial cells, and 2.) a series of site-directed mutations will be generated in an attempt to localize critical amino acids within the minimal domain that are needed for binding and transcytosis. In addition, two approaches will be used to help identify subcellular components in human gut cells that transport the toxin from the apical (viz., mucosal) to the basolateral (viz., serosal) surfaces: 1.) pharmacologic techniques will be used to discriminate clathrin-coated vesicles from lipid raft vesicles, and 2.) immunologic techniques will be used to identify membrane polypeptides that are in or near the binding site for the toxin. It is anticipated that the combined products of this proposed research will provide a clear understanding of botulinum toxin penetration of human cell membranes, with the added benefit of generating a potential vaccine against the toxin. ? ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
3R01NS022153-21S1
Application #
6902983
Study Section
Alcohol and Toxicology Subcommittee 4 (ALTX)
Program Officer
Babcock, Debra J
Project Start
1984-09-01
Project End
2005-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
21
Fiscal Year
2004
Total Cost
$78,500
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Xu, Q; Pichichero, M E; Simpson, L L et al. (2009) An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 16:367-75
Ravichandran, Easwaran; Al-Saleem, Fetweh H; Ancharski, Denise M et al. (2007) Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75:3043-54
Zeng, Mingtao; Xu, Qingfu; Elias, Md et al. (2007) Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 25:7540-8
Ravichandran, Easwaran; Gong, Yujing; Al Saleem, Fetweh H et al. (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318:1343-51
Ahsan, Chowdhury R; Hajnoczky, Gyorgy; Maksymowych, Andrew B et al. (2005) Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J Pharmacol Exp Ther 315:1028-35
Maksymowych, Andrew B; Simpson, Lance L (2004) Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J Pharmacol Exp Ther 310:633-41
Simpson, Lance L; Maksymowych, Andrew B; Park, Jong-Beak et al. (2004) The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. J Pharmacol Exp Ther 308:857-64
Park, Jong-Beak; Simpson, Lance L (2003) Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 71:1147-54
Park, Jong-Beak; Simpson, Lance L; Anderson, Timothy D et al. (2003) Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin. J Voice 17:255-64
Simpson, L L; Maksymowych, A B; Hao, S (2001) The role of zinc binding in the biological activity of botulinum toxin. J Biol Chem 276:27034-41

Showing the most recent 10 out of 42 publications